|
Andropause disease did not exist before
1952 for simple reason that the word
"andropause" did not exist . This word was
introduced in French dictionary in
1952.
Specific treatment of andropause disease
did not exist before
1967 when mesterolone
was put on the market for first time.
There was no specific treatment
for andropause disease before
1968 when
Bruchovsky and Wilson
(pdf)
from Texas University, Dallas,
discovered the conversion of
testosterone to
dihydrotestosterone in the
sexual organs. The same year,
Anderson and Liao
(pdf) from the University of
Chicago,have
discovered specific receptors
for dihydrotestosterone in the
nuclei of prostate cells
Andropause disease diagnosis did not exist
before
1974 year when radioimmulological studies
(RIA) where available in daily medical practice.
Radiommunological
analyses proportioning dihydrotestosterone,
testosterone and their metabolites were
consequently realizable.
of andropause was described for the
first time in
1987 and published on January
4th 1988
by Georges Debled after 14 years' clinical and
radio-immunological studies.
Clinical
and radioimmunological studies
of Georges DEBLED MD. demonstrated since 40
years that a decrease of production in male
hormones produces and worsens the sexual
involution in man; cardiovascular diseases,
arteriosclerosis, angina pectoris, coronary
thrombosis, high sugar, high cholesterol and
lipids in the blood; arthrosis, stiffness and
rheumatism of joins ; nervous breakdown and
brain involution.
Those
phenomenon were described in two pioneer-books
by Dr Georges
DEBLED: L'Andropause, cause,
conséquences et remèdes", Maloine, Paris
1988 and "Au-delà de cette limite votre
ticket est toujours valable", Albin Michel, Paris 1992 et 1994.
In 1992, at an international congress on
ageing in Dallas, Dr Georges DEBLED
presented his theory, according to which the
fall in testosterone secretion is
responsible for male climacteric and ageing
illnesses:
DEBLED
G. The male climacteric, prime cause of
sex involution. The tenth annual
international symposium on man and his
environment in health and disease. February
27 - March 1, 1992, Dallas. Texas. U.S.A.
DEBLED
G.
The male climacteric, prime cause of
aging. The tenth annual international
symposium on man and his environment in
health and disease. February 27 - March 1,
1992, Dallas. Texas. U.S.A.
Conference of Dr Georges Debled on
andropause disease at the Barnes Foundation
USA February 25th
1992
(Video)
You Tube
(56 minutes)
Since this time of many
scientific papers have confirmed this
work:
In 1997,
21 INSERM Unit in France confirmed the
increase
of cardiovascular risk when testosterone
secretion is low in "healthy" adult man :
"Association between plasma total testosterone
and cardiovascular risk factors in healthy adult
men"
in the
Journal
of Clinical Endocrinology and Metabolism (Vol
82, N° 2, p. : 682- 685). This
study known as the
Telecom
study
investigated two groups of men during 8 years
comparing their blood testosterone levels.
Download
pdf.
First group
with normal testosterone during 8 years did not
show any increase of vascular risk during this
period.
Second group
with a decrease of blood testosterone
along the 8 years demonstrated a significant
increase of cardiovascular risk.
In 2006 a study has
demonstrated an
increased mortality
in men with low testosterone
Download pdf.
|
The expressiom
"andropause disease"
corresponds to a
terminological
use of collocations
The main symptom is the
progressive decrease of
sexual activity in the
elderly man (andropause)
This symptom may be
accompanied by general
disorders corresponding
to diseases of
aging (andropause
disease). It is
indeed a disease that
has a
definition of its own.
As this disease is
unknown, its definition
is absent from all
dictionaries.
The expression "androgenic
disease of andropause"
is also suitable for
this
concept published in
January 1988
|
Bibliography
1 .
DEBLED G.- L'Andropause, cause, conséquences et
remèdes. Maloine, Paris, 1988.
2. DEBLED G.
Andropause. 1: Le castrat: un modèle "expérimental". N° 4308 - 24 mai 1989. Le
Quotidien du Médecin. Paris.
3. DEBLED G.
Andropause 2: Dépister pour reculer le vieillissement prématuré.
N° 43 l 3 - 3 l mai 1989. Le Quotidien du
Médecin. Paris.
4.
DEBLED G.
Andropause 3: Sclérose des corps caverneux: le fatalisme n'est plus de mise. N°
4318 - 7 juin 1989. Le Quotidien du Médecin. Paris.
5.
DEBLED G.
Andropause 4: Les troubles "émotionnels" ne doivent pas cacher l'impuissance
organique.
N° 4323 - 14 juin 1989.
Le Quotidien du Médecin. Paris.
6. DEBLED G.
Andropause 5: Les troubles de l'éjaculation. N° 4328 - 21 juin 1989. Le
Quotidien du Médecin. Paris.
7. DEBLED G.
Andropause 6: Les perturbations de la miction. N° 4334 - 29 juin 1989. Le
Quotidien du Médecin. Paris.
8. DEBLED G.
Andropause 7: L'atrophie de la prostate. N° 4372 - 26 septembre 1989. Le
Quotidien du Médecin. Paris. Le Quotidien du Médecin. Paris.
9. DEBLED G.
Andropause 8: Des difficultés mictionnelles à l'insuffisance rénale. N° 4377 - 3
octobre 1989. Le Quotidien du Médecin. Paris.
10.
DEBLED G. Andropause 9: Un âge où "tout se dégrade".N° 4382 - 10 octobre 1989.
Le Quotidien du Médecin. Paris
11.
DEBLED G. Andropause 10: Les hormones sexuelles de l'homme. N4337 - 17 octobre l
989. Le Quotidien du Médecin. Paris.
12.
DEBLED G. Andropause 11: Le généraliste et l'exploration du vieillissement
sexuel. N° 4397 - 31 octobre 1989. Le Quotidien du Médecin. Paris.
13.
DEBLED G. Andropause 12: Les androgènes favorisent-ils l'apparition d'un cancer
de la prostate? N° 4401 - 7 novembre 1989. Le Quotidien du Médecin.
Paris.
14. DEBLED G.
Andropause 13: Le traitement hormonal. N° 4422 - 6 décembre 1989. Le Quotidien
du Médecin.
Paris.
15.
DEBLED G. Au-delà de celle
limite votre ticket est toujours valables. Albin Michel.1992.Paris.
16.
DEBLED G. The male climacteric, prime cause of sex involution.
The Tenth annual international symposium on man and his environment in health
and disease. February 27-March 1, 1992. Dallas. Texas. U.S.A.
17.
DEBLED G. The male climacteric, prime cause of aging. The Tenth annual
international symposium on man and his environment in health and disease.
February 27-March 1, 1992. Dallas. Texas. U.S.A.
18. DEBLED G.
Le traitement hormonal du vieillissement
sexuel de l'homme. Journal de médecine esthétique et de chirurgie
dermatologique.
Vol XXII- N°
85: 7 - 16, 1995
Course
AMERICAN
MEDICAL ASSOCIATION
(AMA) 1993
-Teaching
Seminar
American Academy of family
physicians
DEBLED G: MD.
The
" andropause : The Male climacteric and its consequences" teaching seminar--
Acceptable for 15 hours of prescribed credits by the American Academy of family
physicians, and for 15 hours of category I AMA credits.
Broda O. Barnes M.D. Research Foundation Inc.25-28 March 1993
Scientific Communications
1994
DEBLED G.
L'homme après 50 ans : l'andropause. Le traitement médical du vieillissement
sexuel chez l'homme après 50 ans. Congrès National de Médecine esthétique et de
chirurgie dermatologique.
Paris. 23-25 septembre 1994.
1995
DEBLED G.
L'andropause, mythe ou réalité ? Journées Millavoises de gynécologie obstétrique
et de pédiatrie. Millau, les 9 et 10 juin 1995
1996
DEBLED G. Les principes de l'andropause. Congrès de
gynécologie. 29 mars 1996. Paris.
1997
DEBLED G.
Prévention des sénescences.
La base du maintien du système de vie. Société Belge de Médecine
Esthétique. Premier congrès européen de médecine esthétique et de chirurgie
dermatologique et esthétique. Bruxelles 7-8-9 novembre 1997
1998
DEBLED G.Treatment
of testosterone deficiency in aging male patients.The
European International Conference on Quality of Life and Longevity Medecine.
Brussels 24-26 September 1998.
1999
DEBLED G. Maladies cardio-vasculaires et longévité.
First congress of the EAAA (European Anti-Aging Association).
Brussels
25th September 1999.
DEBLED G. Incidences hormonales dans les alopécies.
Second European congress of aesthetic Medicine and dermatological and plastic
surgery.
Brussels, 24-26 September 1999.
DEBLED G. Les nouveaux traitements hormonaux et leur importance en Médecine
Esthétique.
Second European congress of aesthetic Medicine and dermatological and plastic
surgery.
Brussels, 24-26 September 1999.-
DEBLED G. L'importance des traitements hormonaux dans le maintien de l'apparence
physique.
Second European congress of aesthetic Medicine and dermatological and plastic
surgery.
Brussels, 24-26 September 1999.
2000
DEBLED
G. Comment faire le diagnostic et le traitement de l’andropause ?
Premier
congrès Ibérique de médecine esthétique. Lisbonne, 28-30 avril 2000.
DEBLED G.
Anti-Ageing for Men
13ème
congrès International de Médecine Esthétique. Monaco, 4 Novembre 2000
2001
DEBLED
G.
Androgénothérapie chez l’homme.
Second
congress of the EAAA (European Anti-Aging Association)
Knokke
le Zoute
21th September 2001
DEBLED G: L'andropause, cause, conséquences et remèdes. Société Tunisienne
des Biothérapies. Congrès du XXe Anniversaire. Tunis, 25-28 Octobre 2001
2002
DEBLED G.Testosterona y derivados
Primero congreso de la SEMAL (Sociedad española de Medicina Envejecimiento)
Sevilla 29 noviembre 2002
2003
DEBLED G. Androgènes, clefs du traitement anti-âge ?
Congress of the EAAA (European Anti-Aging Association) dans
le cadre de
l’IMCAS
Paris
11th January 2003.
2004
DEBLED G. Androgénothérapie anti-âge chez l’homme.
Third congress of the EAAA (European Anti-Aging
Association) Brussels
5th
November 2004.
2005
Testosterona.
Congreso de la SEMAL (Sociedad
española de Medicina Envejecimiento).
Sevilla 29 noviembre 2002.
2006
DEBLED G.
La enfermedad
“andropausia”.
Congreso internacional de medicina anti
envejecimiento.
Septiembre 21-22 y 23 de 2006 Club Militar de Bogotá. Bogotá
D.C.
DEBLED G.
Atrofia de la próstata y
envejecimiento.
Congreso internacional de medicina anti
envejecimiento.
Septiembre 21-22 y 23 de 2006 Club Militar de Bogotá. Bogotá
D.C.
DEBLED G.
La enfermedad “andropausia”. Mi experiencia hace 32
años.
International
congress of anti-aging Medicine
Vº
congreso de la sociedad española de medicina anti
envejecimiento y longevidad.
Madrid 3,4 y 5 de Noviembre
2006. Hotel Melia Castilla. Madrid.
|
.png){kind=small}
